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BACKGROUND: In primary breast cancers dichotomic classification of E-cadherin expression, according to an arbitrary cutoff, may be
inadequate and lead to loss of prognostic significance or contrasting prognostic indications. We aimed to assess the prognostic value
of high and low E-cadherin levels in a consecutive case series (204 cases) of unilateral node-negative non-lobular breast cancer
patients with a 8-year median follow-up and that did not receive any adjuvant therapy after surgery.
METHODS: Expression of E-cadherin was investigated by immunohistochemistry and assessed according to conventional score (0, 1þ,
2þ,3 þ). Multiple correspondence analysis was used to visualise associations of both categorical and continuous variables. The
impact of E-cadherin expression on patients outcome was evaluated in terms of event-free survival curves by the Kaplan–Meier
method and proportional hazard Cox model.
RESULTS: Respect to intermediate E-cadherin expression values (2þ), high (3þ) or low (0 to 1þ) E-cadherin expression levels had a
negative prognostic impact. In fact, both patients with a low-to-nil (score 0 to 1þ) expression level of E-cadherin and patients with a
high E-cadherin expression level (score 3þ) demonstrated an increased risk of failure (respectively, hazard ratio (HR)¼1.71,
confidence interval (CI)¼0.72–4.06 and HR¼4.22, CI¼1.406–12.66) and an interesting association with young age.
CONCLUSIONS: The findings support the evidence that high expression values of E-cadherin are not predictive for a good prognosis
and may help to explain conflicting evidence on the prognostic impact of E-cadherin in breast cancer when assessed on
dichotomic basis.
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The adhesion of epithelial cells to their neighbours determines
cellular and tissue morphology, and regulates some major cellular
processes including differentiation, growth and motility. Thus,
disruption of normal cell–cell adhesion in transformed cells
contributes to tumour cells migration and proliferation, leading to
tissue invasion and metastatic spread. Such a disruption can be
achieved by downregulating the expression of cadherin family
members, in particular E-cadherin, whose importance in main-
tenance of normal cell architecture is supported by the observation
that hereditary predisposition to gastric cancer is associated with
germ line mutation in the gene encoding for E-cadherin
(Hirohashi, 1998) or that lobular breast carcinomas frequently
show mutation of CDH1 gene with a decreased E-cadherin
expression (Qureshi et al, 2006). In addition, in vitro and in vivo
experiments have shown that loss of E-cadherin is a crucial step in
metastatic spread allowing malignant cells to migrate into the
surrounding tissue and to enter blood vessels (Frixen et al, 1991;
Birchmeier and Behrens, 1994; Kleer et al, 2001). Consistently, the
downregulation of E-cadherin has been found correlated with
short disease-free survival and poor outcome in many tumour
from epithelial origin, including breast cancer (Asgeirsson et al,
2000; Heimann et al, 2000; Berx and Van Roy, 2001; Lim and Lee,
2002; Pedersen et al, 2002; Rakha et al, 2005; Gould Rothberg and
Bracken, 2006). However, some clinical studies do not support this
evidence (Lipponen et al, 1994; Parker et al, 2001), and there are
conflicting reports about the usefulness of E-cadherin expression
as an independent prognostic marker in invasive breast cancer
(Bukholm et al, 1998; Howard et al, 2004, 2005). In fact, although a
low expression of E-cadherin has been found in invasive
carcinomas without metastases, high E-cadherin levels have been
observed in nodal metastases as compared with their primary
tumour (Beavon, 2000; Kowalski et al, 2003; Harigopal et al, 2005;
Jeschke, 2007). In addition, experimental studies have shown that
E-cadherin-mediated cell–cell adhesion promotes cell survival
protecting tumour cells from chemotherapy and from destruction
while in the circulation as tumour cell clumps (St Croix and
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sKerbel, 1997; Kantak and Kramer, 1998; Gillett et al, 2001; Friedl
et al, 2004). This suggests, on one hand, the inadequacy of the
proposed model for a positive association between favourable
prognosis and E-cadherin expression and, on the other hand, that
immunohistochemical procedures, currently used to quantify
E-cadherin expression, might contribute to the inconsistencies
leading to erroneous prognostic indication, if not to the loss of
prognostic significance for E-cadherin evaluation (Gould Rothberg
and Bracken, 2006). Hence, we performed a retrospective study
aimed to investigate the prognostic impact of E-cadherin
expression, immunohistochemically (IHC) evaluated on a con-
secutive case series of breast cancers. To better dissect the
contribution of E-cadherin expression to prognosis, IHC values
were assessed in expression scores instead of dichotomizing
them according to a pre-defined cutoff. Our findings show that
E-cadherin expression corresponding to 0 to 1þ or 3þ score is
associated with an unfavourable prognosis with respect to score
2þ. This may help to explain conflicting evidence on the
prognostic impact of E-cadherin in breast cancer.
PATIENTS AND METHODS
Patients
We considered 234 consecutive patients who underwent surgery
for a breast cancer between January 1989 and December 1993 at
the Surgical Units of Ferrara S. Anna Hospital University or at
Surgical Units of the Ferrara province’s hospitals. Informed
written consent was obtained from all patients and the study was
approved by the University of Ferrara Research Ethics Committee.
All patients had a non-lobular cancer and did not receive any
adjuvant therapy after surgery because axillary lymph node
negative (pN0) at diagnosis. Additional eligible criteria were:
pathologic stage T1 to T3, availability of at least 10 resected
axillary lymph nodes, absence of synchronous bilateral tumours or
any other malignancy before breast cancer diagnosis and up
to 6 months after surgery, absence of distant metastases at
diagnosis and up to 6 months after surgery, and no neo-adjuvant
therapy. Clinical baseline and patients follow-up data (date and
site of relapse, last follow-up time, date of death and cause of
death) were extracted from the Ferrara Cancer Registry. Data
on patient age, tumour histology, pathologic stage, grading,
oestrogen receptor (ER) and progesterone receptor status were
also collected. After assessment of routine biological markers,
for 204 patients (Table 1), a residual paraffin-embedded tissue
material of the primary tumour was available for the immuno-
histochemical evaluation of E-cadherin expression. The protocol
of this study was approved by the board of the Ministry of
the University and Research (‘Identification and validation of
new markers of metastasizing phenotype of breast cancer’, prot.
MM06095812_006, 2000).
The article was prepared in agreement with the reporting
recommendations for tumour marker reporting studies (McShane
et al, 2005).
Tissue microarrays (TMAs) and E-cadherin IHC
TMA blocks were assembled as follows. A true-cut needle (4mm
in internal diameter) was used to punch 3-mm spaced holes in
the recipient block. Donor blocks of formalin-fixed, paraffin-
embedded archival primary tumour samples were retrieved after re-
evaluation of haematoxylin- and eosin-stained slides. Representative
tumour areas were identified, 4mm diameter cores of tumour
tissues were removed from each donor block and transferred in the
recipient block (24 samples per slide). Tissue microarray was then
incubated for 15min at 371C to allow the tumour cores to firmly
adhere to the recipient block. Consecutive 5-mm thick sections were
cut from the TMA and mounted on polarised slides. Slides were
deparaffined, rehydrated and treated with 3% H2O2 in methanol for
10min to block endogenous peroxidase activity. The slides were
processed in a microwave oven in a TEC buffer (Tris–citrate–
EDTA), pH 7.8, to unmask antigenic sites after formalin fixation.
IHC was performed with an automated immunostainer (Ventana
NEXES, Medical System, Tucson, AZ, USA). Slides were stained
for E-cadherin using the ECH-6 antibody (Medite, Castelnuovo
Del Garda, Italy) and Vectastain ABC peroxidase kit (Vector
Laboratories, DBA Italia, Segrate, Italy) was used to reveal antibody
binding. Slides treated with normal serum or isotype-matched
antibodies were used as negative controls. Endogenous biotin was
saturated with a biotin blocking kit (Vector Laboratories). Two
pathologists (MP and PQ) independently examined all TMA
sections. For each tumour at least 400 cells were counted, and the
percentage of immunostained cells was recorded. E-cadherin
expression was scored according to the product between the
intensity coefficient (0, negative; 1, low; 2, moderate; 3, strong) and
the frequency of positivity coefficient (0, no coloured cells; 1, 1–9%;
2, 10–49%; 3, 50–79%; 4, 80–100%) and categorised as follows: 0,
negative score; 1þ, score 1–4; 2þ, score 5–8; 3þ, score 9–12.
Figure 1 shows some representative examples for different
expression levels of E-cadherin.
Table 1 Clinicopathological characteristics of node-negative breast
cancer patients with available leftover material for E-cadherin evaluation
Categorical variables N %
Age, n¼204
34–40 12 5.88
41–50 45 22.06
51–55 14 6.86
56–70 85 41.67
71–90 48 23.53
Histologic type, n¼204
Cribriform 5 2.45
Ductal 167 81.86
Mucinous 12 5.88
Papillar 5 2.45
Tubular 11 5.39
Medullar 4 1.97
pT stage, n¼204
pT1 159 77.94
pT2 43 21.08
pT3 2 0.08
Histological grade, n¼204
G1 50 24.51
G2 117 57.35
G3 37 18.14
Oestrogen receptor, n¼172
0% 16 9.30
1–10% 24 13.95
410% 132 76.75
Progesterone receptor, n¼169
0% 14 8.28
1–10% 34 20.12
410% 120 71.60
E-cadherin, n¼204
0 92 45.10
1+ 64 31.37
2+ 37 18.14
3+ 11 5.39
Abbreviation: pT stage¼pathological stage.
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sStatistical analysis
The association between E-cadherin and other clinicobiological
markers, namely patient age, histologic type, grading, pT and ER
status was investigated through multiple correspondence analysis
(MCA) that visualises on a bi-dimensional plot the association
of both categorical and continuous variables (Greenacre, 1994;
Marubini and Valsecchi, 1995). For the latter, MCA has the advan-
tage of implying neither linearity nor specific distribution charac-
teristics and to allows to visualise association between markers and
tumours. The points in the plot represent the tumours, whereas the
markers are labelled according to their category. Points close to each
other in a plot correspond to tumours with similar characteristics,
whereas close marker labels correspond to associated marker
categories. The use of a bi-dimensional plot, easy to interpret, is
possible at the expense of loosing some information on the pattern
of associations. The distance between points is based on a w
2 metric,
whereas the measure on the axes do not have any physical meaning.
To help the interpretation of the results, a cluster analysis was
performed using the coordinates of the points, representing
tumours, computed by the MCA. The silhouette index (Kaufman
and Rousseeuw, 1990) was used to select the number of cluster to be
considered.
As reported in Table 1 biological variables were categorized
according to conventional cutoff or score except for patient age
that was subdivided according to physiological-related criteria
(p40 years, young patients; 41–50 years, pre-menopausal patients;
51–55 years, peri-menopausal patients; 56–70 years, post-menopausal
patients; 470 years elderly patients). Cribriform, mucinous, papillary
and tubular histologies were grouped together as ‘other histology’.
To evaluate the effect of E-cadherin on patient outcome, the end
point of the survival analysis was the time elapsed from surgery to the
occurrence of the first adverse event (e.g., local relapse, distant
metastasis, contralateral tumour, a second tumour and death without
evidence of neoplastic disease). Event-free survival curves were plotted
by the Kaplan–Meier method and a proportional hazard Cox model
was applied (Walter et al, 1987). In the multivariable model,
E-cadherin effect was adjusted for grading, pT, age (as continuous
variable) and ER (10% cutoff). Grading categories were coded as two
indicators variables as defined by Walter allowing the comparison
between contiguous levels (Schoenfeld, 1982). Because only two
patients were T3, pathological stages T2 and T3 were grouped toge-
ther. To evaluate the appropriateness of proportional hazard Cox
model assumption Schoenfeld residuals were analysed (Hazan et al,
2000). Hazard ratios (HRs) with 95% confidence intervals (CIs) were
used to quantify the prognostic impact of variables. R software (http://
www.r-project.org) was utilised throughout this study.
RESULTS
Association analysis
Figure 2 shows the plot from the MCA analysis in which the first two
factorial axes explain 95% of the total variability (first axis: 64%;
second axis: 28%). The horizontal axis separates, on the right,
G1, ER410%, ‘other histology’, post-menopaused patients and
E-cadherin 2þ whereas, on the left, low values of ER, G3 and
pre-menopaused patients. The vertical axis mainly separates
E-cadherin score 0 and 3þ. Cluster analysis, performed on the
results of the MCA, highlighted three clusters of patients, represented
in the plot by different colours. The green cluster is characterized by
patients with some favourable characteristics (low tumour histologic
grade, and peri-/post-menopausal status). The black cluster is charac-
terized by pre-menopausal patients having a tumour associated with
Figure 1 Immunohistochemical analysis of E-cadherin expression breast
cancer. (A, B) Ductal infiltrating breast cancers. Both cases express
E-cadherin in almost 100% of the cells, with high, essentially uniform
membrane expression levels (3þ; B) insert: normal breast duct;
corresponding E-cadherin expression levels were utilised as internal
reference (2þ). (C, D) Ductal infiltrating breast cancers. Both cases
express E-cadherin at intermediate levels (2þ). However, in the (C) case
almost 100% of the cells express E-cadherin, whereas a considerable
heterogeneity is observed in the (D) case. (E, F) Representative breast
cancer cases with low (1þ) E-cadherin expression levels. (E) Ductal
infiltrating breast cancer; (F) mucinous-type breast carcinoma.
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Figure 2 Association among E-cadherin (E-cad), oestrogen receptor
(ER), histologic type, grading, pathological stage (pT) and age. Multiple
correspondence analysis plot shows the projections of the categories of
E-cadherin (score 0, 1þ,2þ,3þ), ER (0, p10, 410%), histologic type
(ductal, other), grading (G1, G2, G3) and age (34–40, 41–50, 51–55,
56–70, 71–90). Categories of the variables close to each other correspond
to associated marker categories and clinical characteristics. The coloured points
represented in the plot correspond to the 234 tumours included in the study.
Tumours with similar profiles are projected near to each other. The profiles
are described by the position of the different marker categories. Moreover, to
help interpreting the plot, a cluster analysis was performed to highlight tumours
with similar profiles. Three clusters were chosen using specific indices and the
points coloured accordingly.
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sless favourable characteristics: low ER values and high histologic
grade. The red cluster is mainly composed of young and elderly
patients, having a tumour characterized by an intermediate histologic
grade. E-cadherin 1þ was associated with the black cluster, whereas
E-cadherin 3þ w a sa s s o c i a t e dw i t ht h er e dc l u s t e r .E - c a d h e r i n2 þ
was associated with both green and red clusters while E-cadherin 0 was
associated with both red and black clusters. Noteworthy, E-cadherin
3þ category was plotted near young patients category. Although
this result is based on a low number of patients in E-cadherin 3þ and
34–40 age categories, it suggests a possible interesting association
between high E-cadherin levels and more aggressive disease.
Event-free survival analysis
The follow-up of the study was closed on the 31 December 2002. The
median follow-up of the 204 patients was 118 months even though it
was curtailed at 8 years when only about 12% patients were lost to
follow-up. During follow-up, 23 patients developed distant metas-
tases, 14 a local relapse, 8 a contralateral tumour, 8 another
malignancy and 37 dead as first event. The Kaplan–Meier survival
estimates, according to the different scores of E-cadherin, are shown
in Figure 3. The HR for E-cadherin 1þ vs E-cadherin 0 was 1.04
(P¼0.88), for E-cadherin 2þ vs E-cadherin 1þ was 0.62 (P¼0.22)
and for E-cadherin 3þ vs E-cadherin 2þ was 2.94 (P¼0.03). The
results of the multivariable model are reported in Table 2 where
E-cadherin 0 and 1þ are grouped together. Patients whose tumour
had an E-cadherin expression low-to-nil (score 0 to 1þ)s h o w e d
a tendency toward an increased risk of failure vs patients
with intermediate E-cadherin expression (score 2þ;H R ¼1.71;
CI¼0.72–4.06). Noteworthy, also patients whose tumour expressed
high levels of E-cadherin (score 3þ) had an unfavourable outcome
when compared with patients with E-cadherin 2þ (HR¼4.22;
CI¼1.41–12.66). The prognostic impact of the other variables
analyzed, for example, a lower risk of failure associated with ER
expression, corresponded to that expected from previous studies.
DISCUSSION
Downregulation of the epithelial cell–cell adhesion molecule
E-cadherin is frequently associated with neoplastic transformation
and progression in breast cancer (Asgeirsson et al, 2000; Heimann
et al, 2000; Berx and Van Roy, 2001; Lim and Lee, 2002; Pedersen
et al, 2002; Rakha et al, 2005; Gould Rothberg and Bracken, 2006).
However, there are conflicting reports about the usefulness of
E-cadherin status as an independent prognostic marker in invasive
breast cancer (Lipponen et al, 1994; Bukholm et al, 1998; Parker
et al, 2001; Howard et al, 2004, 2005). Aim of this study was to
assess the relationship between E-cadherin expression levels and
patient outcome. Our findings provide evidence that, with respect
to intermediate values (score 2þ), low-to-nil (score 0 to 1þ)
or high (score 3þ) E-cadherin expression values are associated
with an unfavourable prognosis explaining, at least in part,
the conflicting clinical evidence on the prognostic impact of
E-cadherin when assessed on dichotomic basis.
One of the possible biological explanations of such a finding
could be the epithelial–mesenchymal transition, a process in
which epithelial cells lose their characteristic polarity, disassemble
cell–cell junctions and become more migratory. One of the
most peculiar aspects of epithelial–mesenchymal transition is the
‘cadherin isoform switching’ that consists in a downregulation
of E-cadherin expression and a concomitant upregulation of
N-cadherin with profound effects on cell phenotype and beha-
viour. In fact, upregulation of N-cadherin has been shown to
promote tumour cell motility and invasion (Cavallaro et al, 2002),
according to the ‘cadherin switching’ triggered during normal
embryonic development (Christofori, 2003; Nakajima et al, 2004).
However, the term ‘cadherin switching’ that usually refers to a
switch from E-cadherin to N-cadherin expression, it also includes
situations in which E-cadherin expression levels do not change
significantly from the normal, and cells increase expression of
N-cadherin or co-express inappropriate cadherins including
R-cadherin, cadherin-11 and even P-cadherin altering tumour
cells behaviour towards a more invasive phenotype (Nieman et al,
1999; Tomita et al, 2000; Stefansson et al, 2004; Paredes et al,
2005). In fact, it has been reported that epithelial cells expressing
significant amounts of E-cadherin and just a small amount of
N-cadherin, increase their motility and that a forced expression of
N-cadherin in non-invasive, E-cadherin-positive cells may produce
invasive cells, even though they continue to express high levels of
E-cadherin (Nieman et al, 1999). For example, Hazan et al (2000)
have shown that the non-metastatic breast cancer cell line MCF7
can be transformed in a metastatic cell line when transfected
with N-cadherin and that when injected into the mammary fat pad
of nude mice, these N-cadherin-expressing cells metastasised to
visceral organs whereas control MCF7 cells did not. This suggests
that N-cadherin may activate cell motility even in the presence of
E-cadherin, resulting in a more aggressive and invasive tumour
phenotype. Unfortunately, we were unable to verify such an
interesting biological hypothesis on our case series because of the
dramatic reduction of leftover material that should bias the results.
In conclusion, present results indicate that the IHC evaluation of
E-cadherin expression in terms of negative/positive status should
perhaps be too naive as E-cadherin positivity might actually
hide complex biological interactions that may determine the
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Figure 3 Kaplan–Meier event-free survival curves stratified according to
the expression level of E-cadherin (E-cad). Patients with low-to-nil (score 0
to 1þ) or a high (score 3þ) E-cadherin expression show an increased risk
of relapse with respect to patients with an intermediate E-cadherin
expression level (score 2þ).
Table 2 Risk analysis for event-free survival in a multivariate Cox model
Variable
Coefficient
estimate HR 95% CI P-value
E-cadherin 0–1+ vs 2+ 0.54 1.71 0.722–4.062 0.22
E-cadherin 3+ vs 2+ 1.44 4.22 1.406–12.664 0.01
pT2 vs pT1 0.36 1.44 0.773–2.664 0.25
G2 vs G1 0.03 1.03 0.567–1.880 0.92
G3 vs G2 0.58 1.78 0.756–4.192 0.19
Age 0.05 1.05 1.027–1.072 o0.001
ER 410 vs o10  0.71 0.49 0.261–0.934 0.03
Abbreviations: CI¼confidence interval; ER¼oestrogen receptor; HR¼hazard ratio.
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scourse of tumour progression and disease outcome. A hypothesis
that certainly deserves further investigation.
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